Vixilidea A Novelbest In Class Therapy For Lungneuroendocrineand Other Cancers Based On The Proprietary Somatostatin Peptide Conjugate P2045Treatment With Vixilide Represents A Personalized Approachas Between 80 90Of These Patients Are Known To Overexpress The Targetsomatostatin Receptor 2And The Most Appropriate Patients Having These Tumors Can Be Selected Prior To Therapy By Imagingthis Next Generation Approach Rapidly Kills Cancer Cells And Spares Healthy Tissue
No conferences found for this company.
| Company Name | Andarix Pharmaceuticals |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
